XML 89 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Investments (Notes)
 12 Months Ended
Dec. 31, 2013
Investments [Abstract]  
Investments
Investments

We hold investments in certain publicly traded companies, privately held entities, and limited partnership funds involved primarily in life science and related industries.  Our investments in publicly traded companies are principally marketable equity securities which are accounted for as “available for sale” securities that are carried at their fair values.  Investments in “available for sale” securities with gross unrealized losses as of December 31, 2013, had been in a continuous unrealized loss position for less than 12 months. We have the ability and intent to hold these investments for a reasonable period of time sufficient for the recovery of our investment. We believe that these unrealized losses are temporary, and accordingly have not recognized other-than-temporary impairments related to “available for sale” securities as of December 31, 2013. As of December 31, 2013 and 2012, there were no unrealized losses in our investments in privately held entities.

The following table summarizes our investments as of December 31, 2013 and 2012 (in thousands):
 
December 31,
 
2013
 
2012
“Available-for-sale” marketable equity securities, cost basis
$
2,879

 
$
1,236

Unrealized gains
2,177

 
1,561

Unrealized losses
(587
)
 
(88
)
“Available-for-sale” marketable equity securities, at fair value
4,469

 
2,709

Investments accounted for under cost method
135,819

 
112,333

Investments accounted for under equity method
—

 
6

Total investments
$
140,288

 
$
115,048


    
The following table outlines our investment income, which is classified in other income in the accompanying consolidated statements of income (in thousands):
 
Year Ended December 31,
 
2013
 
2012
 
2011
Investment gains
$
7,050

 
$
15,018

 
$
4,846

Investment losses
(1,480
)
(1) 
(2,637
)
 
(1,795
)
Investment income
$
5,570

 
$
12,381

 
$
3,051


(1)
Includes an impairment loss aggregating $853 thousand primarily related to investment in two private life science companies. During the three months ended December 31, 2013, we reduced the cost basis of an investment in a life science company from $350 thousand to zero. The cost basis of this investment was reduced by $400 thousand and $200 thousand in aggregate during the years ended December 31, 2012 and 2011, respectively, to our estimate of fair value as of the date of each reduction. During the three months ended December 31, 2013, we also reduced the cost basis of another investment in a life science company by $488 thousand to its estimated fair value. This life science company was subsequently acquired by a public company in the first quarter of 2014 at a value approximating our cost basis.